CN103421113B - 抗BLyS抗体 - Google Patents

抗BLyS抗体 Download PDF

Info

Publication number
CN103421113B
CN103421113B CN201210160474.3A CN201210160474A CN103421113B CN 103421113 B CN103421113 B CN 103421113B CN 201210160474 A CN201210160474 A CN 201210160474A CN 103421113 B CN103421113 B CN 103421113B
Authority
CN
China
Prior art keywords
seq
amino acid
blys
acid sequence
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210160474.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103421113A (zh
Inventor
陈博
舒红兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Zhonghe Pharmaceutical Polytron Technologies Inc
WUHAN HUAXIN KANGYUAN BIO-PHARMACEUTICAL Co Ltd
Original Assignee
Shanghai Jun Biomedical Polytron Technologies Inc
WUHAN HUAXIN KANGYUAN BIO-PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201210160474.3A priority Critical patent/CN103421113B/zh
Application filed by Shanghai Jun Biomedical Polytron Technologies Inc, WUHAN HUAXIN KANGYUAN BIO-PHARMACEUTICAL Co Ltd filed Critical Shanghai Jun Biomedical Polytron Technologies Inc
Priority to US14/401,288 priority patent/US9828423B2/en
Priority to EP13794561.4A priority patent/EP2853543B1/en
Priority to PCT/CN2013/076074 priority patent/WO2013174264A1/zh
Priority to IN2367MUN2014 priority patent/IN2014MN02367A/en
Priority to JP2015511926A priority patent/JP6006404B2/ja
Priority to EP20180342.6A priority patent/EP3792280A3/en
Priority to BR112014025651-9A priority patent/BR112014025651B1/pt
Priority to RU2014133410A priority patent/RU2613422C2/ru
Publication of CN103421113A publication Critical patent/CN103421113A/zh
Priority to ZA2014/08955A priority patent/ZA201408955B/en
Application granted granted Critical
Publication of CN103421113B publication Critical patent/CN103421113B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201210160474.3A 2012-05-22 2012-05-22 抗BLyS抗体 Active CN103421113B (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201210160474.3A CN103421113B (zh) 2012-05-22 2012-05-22 抗BLyS抗体
RU2014133410A RU2613422C2 (ru) 2012-05-22 2013-05-22 Антитело к blys
PCT/CN2013/076074 WO2013174264A1 (zh) 2012-05-22 2013-05-22 抗BLyS抗体
IN2367MUN2014 IN2014MN02367A (enExample) 2012-05-22 2013-05-22
JP2015511926A JP6006404B2 (ja) 2012-05-22 2013-05-22 抗ＢＬｙＳ抗体
EP20180342.6A EP3792280A3 (en) 2012-05-22 2013-05-22 Anti-blys antibody
US14/401,288 US9828423B2 (en) 2012-05-22 2013-05-22 Anti-BLyS antibody
EP13794561.4A EP2853543B1 (en) 2012-05-22 2013-05-22 Anti-blys antibody
BR112014025651-9A BR112014025651B1 (pt) 2012-05-22 2013-05-22 Anticorpo anti-blys, seu método de preparação, composição farmacêutica, vetor de dna recombinante e molécula de dna
ZA2014/08955A ZA201408955B (en) 2012-05-22 2014-12-05 Anti-blys antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210160474.3A CN103421113B (zh) 2012-05-22 2012-05-22 抗BLyS抗体

Publications (2)

Publication Number Publication Date
CN103421113A CN103421113A (zh) 2013-12-04
CN103421113B true CN103421113B (zh) 2018-01-19

Family

ID=49623127

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210160474.3A Active CN103421113B (zh) 2012-05-22 2012-05-22 抗BLyS抗体

Country Status (8)

Country Link
US (1) US9828423B2 (enExample)
EP (2) EP2853543B1 (enExample)
JP (1) JP6006404B2 (enExample)
CN (1) CN103421113B (enExample)
IN (1) IN2014MN02367A (enExample)
RU (1) RU2613422C2 (enExample)
WO (1) WO2013174264A1 (enExample)
ZA (1) ZA201408955B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615672D0 (en) 2006-08-07 2006-09-13 Rencol Tolerance Rings Ltd Assembly of a shaft and a housing assembly
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
CN104804092B (zh) * 2014-01-29 2018-03-27 天津胜发生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体及其用途
CN104804090B (zh) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体和用途
CN104804091B (zh) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体及用途
EP3151857A4 (en) * 2014-06-03 2018-04-18 Merck Sharp & Dohme Corp. Anti-blys antibodies
CN104628856A (zh) * 2015-01-23 2015-05-20 中国人民解放军军事医学科学院放射与辐射医学研究所 一种抗BLyS单链抗体及其制备方法和用途
CN105061596B (zh) * 2015-08-05 2019-01-29 江苏诺迈博生物医药科技有限公司 人b淋巴细胞刺激因子的单克隆抗体及其应用
CN106916224B (zh) * 2015-12-28 2021-03-23 中国人民解放军军事医学科学院放射与辐射医学研究所 抗b淋巴细胞刺激因子单克隆抗体及其制备方法和用途
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
WO2018006824A1 (zh) * 2016-07-06 2018-01-11 上海开拓者生物医药有限公司 一种BLyS抗体及其制备方法和应用
CA3092434A1 (en) * 2017-02-27 2018-08-30 Caerus Therapeutics, Inc. Compositions of a novel anti-human ceacam6 antibody and uses thereof
WO2020160199A1 (en) * 2019-01-31 2020-08-06 Siemens Healthcare Diagnostics Inc. Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
CN112111461B (zh) * 2020-08-17 2022-08-30 浙江正熙生物医药有限公司 一种单细胞分选构建单克隆抗体高产株细胞工作库的方法
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
JP2025533898A (ja) * 2022-10-07 2025-10-09 アブウィズ バイオ，インコーポレイテッド 抗ｉｇｅ抗体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101851291A (zh) * 2010-02-09 2010-10-06 中国人民解放军第四军医大学 一种抗人baff单克隆抗体的重链和轻链可变区

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939804B2 (en) * 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2003055979A2 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
US20020150579A1 (en) * 2002-01-10 2002-10-17 Kimberly Robert P. B lymphocyte stimulator (BLyS) as a marker in management of systemic lupus erythematosus
CN1168831C (zh) 2002-05-24 2004-09-29 张志方 一种重组人b淋巴细胞刺激因子表达载体的构建、dna免疫制备单克隆抗体及其应用
RU2005141541A (ru) * 2003-06-05 2006-06-27 Дженентек, Инк. (Us) Комбинированная терапия в-клеточных нарушений
MXPA06004301A (es) * 2003-10-20 2006-06-05 Biogen Idec Inc Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101851291A (zh) * 2010-02-09 2010-10-06 中国人民解放军第四军医大学 一种抗人baff单克隆抗体的重链和轻链可变区

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B淋巴细胞刺激物单克隆抗体的制备与特性鉴定;石晓娟等;《细胞与分子免疫学杂志》;20050518(第3期);第328-329页 *

Also Published As

Publication number Publication date
WO2013174264A1 (zh) 2013-11-28
RU2014133410A (ru) 2016-07-10
US20150259409A1 (en) 2015-09-17
EP3792280A2 (en) 2021-03-17
RU2613422C2 (ru) 2017-03-16
CN103421113A (zh) 2013-12-04
EP3792280A3 (en) 2021-07-21
ZA201408955B (en) 2015-12-23
IN2014MN02367A (enExample) 2015-08-14
JP2015517505A (ja) 2015-06-22
JP6006404B2 (ja) 2016-10-12
EP2853543A8 (en) 2015-05-13
EP2853543A1 (en) 2015-04-01
EP2853543B1 (en) 2020-09-02
EP2853543A4 (en) 2016-03-30
US9828423B2 (en) 2017-11-28
BR112014025651A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
CN103421113B (zh) 抗BLyS抗体
AU2019358647B2 (en) Novel anti-c-kit antibody
US10822421B2 (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
EP3081576B1 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
US20120308575A1 (en) Full human anti-tnf-alpha monoclonal antibody, preparation method and use thereof
CA3194384A1 (en) Caninized rat antibodies to canine interleukin-31 receptor alpha
WO2021088904A1 (zh) 抗人程序性死亡配体-1(pd-l1)的抗体及其用途
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
WO2022001189A1 (zh) 一组gitr单克隆抗体及其医药用途
CN116133684B (zh) 抗人nr1抗体衍生物
CN109384845A (zh) 一种cd40单克隆抗体、其制备方法及其应用
CN108893449A (zh) 杂交瘤细胞、抗人亲环素蛋白a的单克隆抗体及其应用
WO2015113494A1 (zh) 双功能融合蛋白及其制备方法和用途
CN116574189A (zh) 针对人il-36r和/或人il-1r3的多种抗体及其用途
WO2022179516A1 (zh) 抗TrkA抗体或其抗原结合片段、其制备方法和应用
CN108635579A (zh) 抗人bFGF纳米抗体在制备治疗黑色素瘤药物中的应用
CN114269788B (zh) 一种能够与人4-1bb结合的分子及其应用
CN114456267A (zh) 一种抗cd73人源化单克隆抗体及其应用
CN105037548B (zh) 抗人白介素-6受体β链单克隆抗体、其制备方法和用途
CN105294863A (zh) 双功能抗体及其用途
CN111234021B (zh) 一种抗ccr5抗体及其在治疗肿瘤中的应用
WO2020132857A1 (zh) 抗ox40的单克隆抗体及其应用
BR112014025651B1 (pt) Anticorpo anti-blys, seu método de preparação, composição farmacêutica, vetor de dna recombinante e molécula de dna
CN118525034A (zh) 犬白介素-31受体αI的犬源化抗体
CN110922483A (zh) 抗ccr5抗体及其在治疗肿瘤中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
ASS Succession or assignment of patent right

Owner name: SHANGHAI UNION BIOPHARM CO., LTD.

Effective date: 20150506

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150506

Address after: 430075 No. 666, hi tech Avenue, East Lake New District, Hubei, Wuhan

Applicant after: Wuhan Huaxin Kangyuan Bio-Pharmaceutical Co., Ltd.

Applicant after: Shanghai Zhonghe pharmaceutical Polytron Technologies Inc

Address before: 430075, B1 building, building, B, C and D District, Wuhan hi tech Avenue, East Lake Development Zone, Wuhan, Hubei

Applicant before: Wuhan Huaxin Kangyuan Bio-Pharmaceutical Co., Ltd.

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 430075 No. 666, hi tech Avenue, East Lake New District, Hubei, Wuhan

Applicant after: Wuhan Huaxin Kangyuan Bio-Pharmaceutical Co., Ltd.

Applicant after: Shanghai Jun biomedical Polytron Technologies Inc

Address before: 430075 No. 666, hi tech Avenue, East Lake New District, Hubei, Wuhan

Applicant before: Wuhan Huaxin Kangyuan Bio-Pharmaceutical Co., Ltd.

Applicant before: Shanghai Zhonghe pharmaceutical Polytron Technologies Inc

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant